CTVA Corteva, Inc.

NYSE corteva.com


$ 63.53 $ 0.00 (0 %)    

Wednesday, 05-Nov-2025 06:46:37 EST
QQQ $ 619.54 $ 0.00 (0 %)
DIA $ 471.27 $ 0.00 (0 %)
SPY $ 675.72 $ 0.00 (0 %)
TLT $ 89.45 $ 0.00 (0 %)
GLD $ 365.60 $ 0.00 (0 %)
$ 62.5
$ 61.91
$ 63.50 x 101
$ 64.35 x 10
-- - --
$ 53.14 - $ 77.22
5,189,559
na
42.44B
$ 0.75
$ 30.30
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-14-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 02-08-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-04-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-09-2023 12-31-2022 10-K
12 11-04-2022 09-30-2022 10-Q
13 08-05-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-10-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-06-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 02-11-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 02-14-2020 12-31-2019 10-K
24 10-31-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-31-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 corteva-expects-to-repurchase-about-1b-of-shares-in-2025

The Company updated full-year 2025 guidance with net sales expected to be in the range of $17.7 billion to $17.9 billion, growt...

 corteva-raises-fy2025-adj-eps-guidance-from-300-320-to-325-335-vs-313-est-raises-fy2025-sales-guidance-from-17600b-17800b-to-17700b-17900b-vs-17603b-est

Corteva (NYSE:CTVA) raises FY2025 Adj EPS guidance from $3.00-$3.20 to $3.25-$3.35 vs $3.13 analyst estimate. Raises FY2025 sal...

 corteva-q3-adj-eps-023-beats-053-estimate-sales-2618b-beat-2473b-estimate

Corteva (NYSE:CTVA) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.53) by 56.7...

 palantir-weighs-on-wall-street-bitcoin-slumps-5-whats-moving-markets-tuesday

Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, o...

 ubs-maintains-buy-on-corteva-lowers-price-target-to-81

UBS analyst Joshua Spector maintains Corteva (NYSE:CTVA) with a Buy and lowers the price target from $85 to $81.

 wells-fargo-maintains-overweight-on-corteva-lowers-price-target-to-80

Wells Fargo analyst Richard Garchitorena maintains Corteva (NYSE:CTVA) with a Overweight and lowers the price target from $8...

 trumps-next-trade-long-us-ag-tech-short-china-inputs

Trump's warning to end business with China highlights food trade as ag-tech industries benefit and Chinese suppliers may be...

 argus-research-maintains-buy-on-corteva-lowers-price-target-to-80

Argus Research analyst Alexandra Yates maintains Corteva (NYSE:CTVA) with a Buy and lowers the price target from $83 to $80.

 mizuho-maintains-outperform-on-corteva-lowers-price-target-to-78

Mizuho analyst John Roberts maintains Corteva (NYSE:CTVA) with a Outperform and lowers the price target from $85 to $78.

 ubs-maintains-buy-on-corteva-lowers-price-target-to-85

UBS analyst Joshua Spector maintains Corteva (NYSE:CTVA) with a Buy and lowers the price target from $91 to $85.

 deal-dispatch-from-stellantis-to-snyk-major-companies-consider-exits

Berkshire agreed to buy OxyChem for $9.7 billion while EA goes private for $55 billion. Also, Middleby seeks a $800 million deal.

 keybanc-downgrades-corteva-to-sector-weight

Keybanc analyst Aleksey Yefremov downgrades Corteva (NYSE:CTVA) from Overweight to Sector Weight.

 citigroup-downgrades-corteva-to-neutral-lowers-price-target-to-67

Citigroup analyst Patrick Cunningham downgrades Corteva (NYSE:CTVA) from Buy to Neutral and lowers the price target from $83...

 jp-morgan-upgrades-corteva-to-overweight-announces-70-price-target

JP Morgan analyst Jeffrey Zekauskas upgrades Corteva (NYSE:CTVA) from Neutral to Overweight and announces $70 price target.

 health-care-stocks-rally-nike-beats-the-street-whats-moving-markets-wednesday

Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps m...

 corteva-expects-dis-synergies-of-80m-to-100m-related-to-spinoff-says-legacy-liabilities-including-pfas-obligations-will-be-retained-by-new-corteva

- Conf Call

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION